Search

Displaying results 1511 - 1520 of 4300 in total
  1. Drug

    Golodirsen

    go.drugbank.com/drugs/DB15593
    ApprovedInvestigational

    Often, patients succumb to this condition by age 30 or younger due to cardiac and respiratory complications. … This is an X-linked condition leading to progressive muscle degeneration that begins in early childhood, rendering many patients wheelchair-bound by age 12.

  2. Drug

    Levosimendan

    go.drugbank.com/drugs/DB00922
    ApprovedInvestigationalWithdrawn

    Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. … It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.

  3. Drug

    Tuxobertinib

    go.drugbank.com/drugs/DB21508
    Investigational

    Tuxobertinib is under investigation in clinical trial NCT04209465 (A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.).

  4. Drug

    Pancrelipase protease

    go.drugbank.com/drugs/DB11066
    ApprovedInvestigational

    [L2509] The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion. … [A32742, L2543] The pancrelipase mixture, including pancrelipase protease, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]

  5. Drug

    Calcium gluconate

    go.drugbank.com/drugs/DB11126
    ApprovedInvestigationalVet approved

    It can also be taken by mouth but is not recommended by injection into a muscle.

  6. Drug

    Tenofovir alafenamide

    go.drugbank.com/drugs/DB09299
    ApprovedInvestigational

    [T239] Tenofovir alafenamide is an alanine ester form characterized for presenting low systemic levels but high intracellular concentration. … [L4388,L9010] Tenofovir alafenamide was developed by Gilead Sciences Inc and granted FDA approval on 5 November 2015.[L6271]

  7. Drug

    Polihexanide

    go.drugbank.com/drugs/DB12277
    ApprovedInvestigational

    [A1351,A273908] Polihexanide is approved in Europe under the name Akantior for the treatment of _Acanthamoeba_ keratitis, an ocular infection caused by the _Acanthamoeba_ parasite. … Structurally, it consists of repeating biguanide units linked by hexamethylene hydrocarbon chains, conferring both hydrophilic and hydrophobic properties that enhance its interaction with microbial membranes

  8. Drug

    Sulfasalazine

    go.drugbank.com/drugs/DB00795
    ApprovedInvestigational

    [A255582] Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970. … [A255582] Although sulfasalazine is only approved by the FDA for ulcerative colitis, research have shown that sulfasalazine is also beneficial for patients with Crohn's disease.

  9. Drug

    Ustekinumab

    go.drugbank.com/drugs/DB05679
    ApprovedInvestigational

    Ustekinumab biosimilars are available in some markets, including Wezlana,[L49071] Yesintek,[L52815] Selarsdi,[L52820] Otulfi,[L52825] and Pyzchiva[L52810] in the US, Jamteki (AVT04),[L49076] Steqeyma,[ … In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults.

  10. Drug

    Tizanidine

    go.drugbank.com/drugs/DB00697
    ApprovedInvestigational

    Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons … It may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition.